secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2021-10-28T23:59:59+00:00
Accession:  0001193125-21-310286
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio's COVID-19 vaccine INO-4800 selected for WHO Solidarity Trial Vaccines Phase 3
--------------------------------------------------------------------------------

- WHO confirmed Oct 26, 2021 that INO-4800 is one of two vaccines in large international Phase 3 Solidarity Trial.
- Selected by independent advisory group from ~20 candidate vaccines; two more vaccines may enter later.
- Trial recruiting volunteers at over 40 sites across Colombia, Mali, and the Philippines.
- Inovio also conducting separate global Phase 3 INNOVATE trial with partner Advaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312521310286/0001193125-21-310286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312521310286/d235597d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-310286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer